Largactil

Chlorpromazine, the active ingredient in Largactil, is a phenothiazine antipsychotic presented as an injectable formulation for intramuscular and intravenous use. It is employed to manage schizophrenia, acute psychosis, severe agitation, and nausea or vomiting in adult patients.

GNH USA supplies Largactil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable logistics for bulk and individual orders, with regulatory compliance, temperature‑controlled shipping where required, and responsive customer support throughout the supply chain.

Chlorpromazine is a phenothiazine antipsychotic used to treat several psychiatric and gastrointestinal conditions. - Schizophrenia: reduces psychotic symptoms such as delusions, hallucinations and thought disorder. - Acute psychosis: provides rapid calming and symptom control during severe episodes. - Severe agitation: calms intense restlessness and aggressive behavior. - Nausea and vomiting: blocks central pathways to alleviate refractory emesis.

Adverse reactions may occur with chlorpromazine therapy.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dry mouth: reduced salivation leading to oral discomfort. - Orthostatic hypotension: dizziness upon standing due to blood pressure drop. - Weight gain: increase in body weight over time. - Constipation: slowed gastrointestinal motility. - Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects: - Extrapyramidal symptoms: muscle rigidity, tremor, or involuntary movements. - Neuroleptic malignant syndrome: life‑threatening fever, rigidity and autonomic instability. - Tardive dyskinesia: persistent involuntary facial or limb movements. - Severe hypotension: marked drop in blood pressure causing fainting. - Agranulocytosis: dangerous reduction in white blood cells. - Cardiac arrhythmias: irregular heart rhythms, especially with pre‑existing heart disease.

Chlorpromazine requires careful monitoring in several clinical situations. - Cardiac monitoring: observe for QT prolongation and arrhythmias. - CNS depression: avoid concurrent sedatives that may enhance drowsiness. - Elderly patients: start low and watch for confusion or falls. - Liver impairment: adjust dose if hepatic function is reduced. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Chlorpromazine can interact with a range of medicines.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: risk of hypertensive crisis. - Anticholinergic drugs: may exacerbate dry mouth and constipation. - QT‑prolonging agents: increase chance of serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CNS depressants (benzodiazepines, opioids): enhanced sedation. - CYP2D6 inhibitors (e.g., fluoxetine): may raise chlorpromazine levels. - Antihypertensives: additive blood pressure lowering effect.